SEC FORM 4SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
checkbox uncheckedCheck this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
checkbox checkedCheck this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Megna Michael R

(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR

(Street)
LONDONW1J 7NJ

(City)(State)(Zip)
UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]
Foreign Trading Symbol
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
checkbox checkedOfficer (give title below)Other (specify below)
CHIEF ACCOUNTING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
checkbox checkedForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share10/30/2026M(1)4,689A$10.7633,751D
Class A Ordinary Share10/30/2026M(1)3,932A$11.137,683D
Class A Ordinary Share10/30/2026M(1)7,209A$11.9744,892D
Class A Ordinary Share10/30/2026M(1)4,065A$17.7648,957D
Class A Ordinary Share10/30/2026S(1)6,030D$91.87(2)42,927D
Class A Ordinary Share10/30/2026S(1)6,831D$92.77(3)36,096D
Class A Ordinary Share10/30/2026S(1)9,508D$94.2(4)26,588D
Class A Ordinary Share10/30/2026S(1)3,705D$94.86(5)22,883D
Class A Ordinary Share10/30/2026S(1)3,145D$96.08(6)19,738D
Class A Ordinary Share10/30/2026S(1)1,691D$97.11(7)18,047D
Class A Ordinary Share10/30/2026S(1)5,350D$97.74(8)12,697D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$11.110/30/2026M(1)3,932 (9)04/06/2032Class A Ordinary Share3,932$00D
Share Option$11.9710/30/2026M(1)7,209 (9)08/31/2032Class A Ordinary Share7,209$00D
Share Option$10.7610/30/2026M(1)4,689 (10)03/31/2033Class A Ordinary Share4,689$02,983D
Share Option$17.7610/30/2026M(1)4,065 (11)08/31/2033Class A Ordinary Share4,065$016,394D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.275 and $92.26. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.28 and $93.27. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.38. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
7. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
8. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
9. The option is fully vested and exercisable.
10. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
11. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
/s/ Douglas Barry, Attorney-in-Fact11/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.